NCT03953456View on ClinicalTrials.gov

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

March 11, 2020

Study Completion Date

July 14, 2020

Conditions
Non-Alcoholic Fatty Liver
Interventions
DRUG

elafibranor 120mg

elafibranor 120mg is a coated tablet for oral administration, once daily

DRUG

Placebo

Placebo is a coated tablet for oral administration, once daily

Trial Locations (1)

Unknown

NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht

Sponsors

Lead Sponsor

Genfit
All Listed Sponsors
lead

Genfit

INDUSTRY

NCT03953456 - Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL) | Biotech Hunter | Biotech Hunter